Cost savings and health gains estimated from achievement of the US Food and Drug Administration voluntary sodium reformulation targets
Pearson-Stuttard J et al recently published a paper in PLoS Medicine estimating the health and economic effects of the proposed US Food and Drug Administration (FDA) voluntary sodium reformulation. The US IMPACT Food Policy Model was used to estimate cost-effectiveness and health impact of three scenarios; 100% compliance with 10-year reformulation targets, 50% compliance with 10-year reformulation targets and 100% compliance with 2-year reformulation targets. It was found that the first scenario, achieveing the FDA targets, could prevent 450,000 CVD cases and produce discounted cost savings (health savings – policy costs) of approximately $41 billion, the cost savings for the other two scenarios would be $19 billion and $12 billion respectively. Authors concluded that achievement of the FDA targets could produce health gains and cost savings.
Read more here.